focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
"'Approaching £500m". The deal valued Ithica at £519m. https://www.telegraph.co.uk/business/2017/02/06/delek-bid-buy-ithaca-energy-12bn-deal-sparks-shareholder-protest/
Short term: Last two weeks of March for funding. Rise in anticipation hopefully, possible derisking too closer to news in case it doesn't happen. Don't think usual Aim sell on news (even good news) applies. Company will be worth more than £25m on funding and there's still the 30th round (q2?) catalyst to retain interest.
The Proactive interview and today's Vox interview were good. The third of those four routes to market - about linking up with other companies who have antibiotics coming to market this year - I found interesting. The Vox interview mentioned that iclaprim can save hospitals $17,000 for every patient that gets an acute kidney injury through vancomycin - I guess they just have to drum this message home now. Quality of board/science has never seemed in doubt to me but reassuring interviews nonetheless.
I don't think I've read anybody saying it's a done deal. Upbeat, hopeful and positive, sure. With only 34m shares about and with the bod holding a fair chunk, it could rise at a fair old lick on the back of good news. Here's hoping.
Can be many reasons. It could be City Financial reducing and offloading the remainder of their holding, about 4% now. Bad news? No, look into them, it's what they do and how they work. It can be private investors, some who got in while the sp was circa 30, taking the risk out of their investment, returning their stake to their accounts and letting the rest ride, a common strategy. It could be holders of placing shares offloading, healthy profit etc. It can be PIs, who having got in the 70s, cutting their losses at the first sign of a drop, in line with their particular trading strategy. It's a market, there's two sides. Read and research, absorb it all and have a plan and stick to it. I've only been interested in shares for two years or so, it's fascinating - both the businesses themselves and the people who invest in them - and you never stop learning. Good luck.
Makes the Twitter group sound like the Stonecutters off The Simpsons. Is there a special handshake or can any Tom Dick join?
Fair point. Was alluding more at irritation for tlou at time wasted - by both sides. Mad how a co can company submit a tender knowing it doesn't meet all the criteria. Arrogance or confidence? Anyway, is done now and still seems plenty of appetite for the share. Reserves update pls soon tlou. Atb.
Imm placing at 144 didn't help and it seems to be in a derisking phase. Different beast to here, mind. Was there takeover talk with Paratek but nothing materialised? One would give the sector a much-needed shot in the arm you'd think. I thought the big pharma would be queuing up for akao, paratek & mtfb by now.
This share remains my no1 aim holding, I like its science, the results it has accomplished and possible market for its drug. But it is one mighty test of patience and when making a first buy I did not cater for its curious market manoeuvres, auto trades or spoofing - in that sense it has been an education. My fear, however irrational, is that come November, there will be news as follows, ''Motif were delighted to announce that the FDA approved its novel antibiotic iclaprim today. Shares in Motif soared 40% to 50p on opening before dropping back in trading'. Jimbob posted this vid on mtfb spoofing on twitter. https://www.youtube.com/watch?v=0dxvSqxWqxw&feature=youtu.be
Would anyone or an organisation put 400k on a stop loss? Seems a curious thing to do. I presume Amp are still holding strong...
Replacement a former Amphion partner. And they've done great. Reacted to this with at best indifference, much like when Everton hired Big Sam. Prefer a reason was given, market doesn't like vagueness. Hopefully all irrelevant to the final outcome.
Could a shareprofits article have caused a bit of consternation? How much short-term influence do they have? Who cares, though. 20 year US patent, future licensing and directors needing this above 3p for 90 consecutive days to exercise options are all plus points.
Either (a) bit of profit taking/derisking ahead of next week or (b) sharp drop for market makers to accumulate shares for expected rise. Nothing unusual. Looking forward to update.
I don't think anything in particular is happening in June. It is a 6 month extension from January 15, a kick down the line and probably the best deal they could get. Amp no doubt want to be in mtfb for as long as they can, by then we'd have had NDA in q1 and the FDA's two-month acknowledgment of receipt by then. Hopefully a rerate by then. I presume Amp hoped we'd have rerated by now.